Predict your next investment

HEALTHCARE | Biotechnology
allos.com

See what CB Insights has to offer

Founded Year

1992

Stage

Acq - P2P | Acquired

Total Raised

$66.61M

Valuation

$0000 

Revenue

$0000 

About Allos Therapeutics

Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX) is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pralatrexate in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins lymphoma (NHL). Allos currently retains exclusive worldwide rights to pralatrexate and RH1 for all indications.In September 2012, Allos Therapeutics was acquired by Spectrum Pharmaceuticals. The valuation of Allos Therapeutics was undisclosed. Other terms of the deal were not released.

Allos Therapeutics Headquarter Location

11080 Circlepoint Road Suite 200

Westminster, Colorado, 80020,

United States

303-426-6262

Latest Allos Therapeutics News

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Jul 21, 2012

googlecse  Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics Charles Gross , Benzinga Staff Writer   {{following ? "Following" : "Follow"}} July 20, 2012 6:41pm   Comments Share: Spectrum Pharmaceuticals (NASDAQ: SPPI ) and Allos Therapeutics (NASDAQ: ALTH ) announced Friday that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any applicable withholding taxes. The extension was made in order for Spectrum and Allos to continue cooperating with the Federal Trade Commission in relation to the previously announced Request for Additional Information and Documentary Material that each party received on May 9, 2012 from the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Allos by Spectrum. The offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Monday, July 23, 2012, has been extended until 5:00 p.m., Eastern time, on Monday, August 6, 2012, unless extended for an additional period. All terms and conditions of the tender offer shall remain unchanged during the extended period. The depositary for the tender offer has advised Spectrum that, as of 5:00 p.m., Eastern time, on July 20, 2012, a total of approximately 65,241,335 shares of Allos common stock, representing approximately 61.0% of the outstanding shares of Allos common stock, were validly tendered and not withdrawn. © 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Allos Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Allos Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Allos Therapeutics Patents

Allos Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2013

2/27/2018

Experimental cancer drugs, Lung cancer, Monoclonal antibodies, Monoclonal antibodies for tumors, Fluoroarenes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/17/2013

00/00/0000

00/00/0000

Grant Date

2/27/2018

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Experimental cancer drugs, Lung cancer, Monoclonal antibodies, Monoclonal antibodies for tumors, Fluoroarenes

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.